Q1 2023 Earnings Forecast for Codex DNA, Inc. (NASDAQ:DNAY) Issued By Jefferies Financial Group

Codex DNA, Inc. (NASDAQ:DNAYGet Rating) – Equities research analysts at Jefferies Financial Group issued their Q1 2023 earnings estimates for Codex DNA in a report issued on Wednesday, May 11th. Jefferies Financial Group analyst B. Couillard anticipates that the company will earn ($0.32) per share for the quarter. Jefferies Financial Group also issued estimates for Codex DNA’s Q2 2023 earnings at ($0.26) EPS, Q3 2023 earnings at ($0.35) EPS and Q4 2023 earnings at ($0.46) EPS.

Codex DNA (NASDAQ:DNAYGet Rating) last posted its quarterly earnings data on Tuesday, March 22nd. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The company had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $3.83 million. Codex DNA had a negative return on equity of 43.84% and a negative net margin of 311.52%.

Other analysts have also recently issued research reports about the company. Cowen initiated coverage on Codex DNA in a research report on Wednesday, March 2nd. They set a “buy” rating for the company. KeyCorp decreased their price target on Codex DNA from $30.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, March 28th. Finally, Zacks Investment Research raised Codex DNA from a “sell” rating to a “hold” rating in a research note on Monday, May 2nd.

Codex DNA stock traded up $0.14 during midday trading on Friday, reaching $3.84. 25 shares of the company were exchanged, compared to its average volume of 214,201. The company has a market capitalization of $112.90 million and a price-to-earnings ratio of -1.62. The firm’s 50-day simple moving average is $5.94 and its 200-day simple moving average is $7.43. Codex DNA has a 1 year low of $3.43 and a 1 year high of $25.70. The company has a debt-to-equity ratio of 0.16, a quick ratio of 9.33 and a current ratio of 9.57.

Large investors have recently modified their holdings of the business. BlackRock Inc. lifted its stake in shares of Codex DNA by 66.8% in the 3rd quarter. BlackRock Inc. now owns 333,471 shares of the company’s stock valued at $3,712,000 after purchasing an additional 133,512 shares in the last quarter. Strs Ohio lifted its stake in shares of Codex DNA by 1,150.0% in the 4th quarter. Strs Ohio now owns 22,500 shares of the company’s stock valued at $243,000 after purchasing an additional 20,700 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of Codex DNA by 33.4% in the 3rd quarter. Franklin Resources Inc. now owns 732,900 shares of the company’s stock valued at $8,157,000 after purchasing an additional 183,700 shares in the last quarter. Deutsche Bank AG acquired a new position in shares of Codex DNA in the 3rd quarter valued at about $50,000. Finally, California State Teachers Retirement System acquired a new position in shares of Codex DNA in the 3rd quarter valued at about $47,000. 87.58% of the stock is currently owned by hedge funds and other institutional investors.

About Codex DNA (Get Rating)

Codex DNA, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis.

Featured Stories

Earnings History and Estimates for Codex DNA (NASDAQ:DNAY)

Receive News & Ratings for Codex DNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codex DNA and related companies with MarketBeat.com's FREE daily email newsletter.